Morgan Stanley raised the firm’s price target on Incyte (INCY) to $92 from $86 and keeps an Equal Weight rating on the shares after management presented updated Phase 1 data for its mutant CALR antibody INCA033989 in myelofibrosis patients at the ASH meeting. Following the meeting, the firm adjusted its view of the odds of success for the program to 35%, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Galecto price target raised to $36 from $32 at Guggenheim
- Incyte’s Mutant CALR Antibody Shows Promise but Faces Uncertainties: Hold Rating Issued
- Incyte’s INCA033989: Promising Myelofibrosis Treatment Drives Buy Rating
- Incyte upgraded to Outperform from Neutral at Mizuho
- Incyte price target raised to $116 from $97 at Wells Fargo